SCHEMBL26633832

SCHEMBL26633832

COc1ccc(CNC(=O)NC2CC3(C2)CN(C(=O)CCc2ccccc2Cl)C3)cc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ MCHR1 Q99705 3/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ CXCR4 P61073 1/20 0.42
▸ NPFFR1 Q9GZQ6 2/20 0.42
▸ NPFFR2 Q9Y5X5 2/20 0.42
▸ GHSR Q92847 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ENPP2 Q13822 1/20 0.41
▸ ATXN2 Q99700 1/20 0.41
▸ GFER P55789 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30306671 0.91 NPC1 (0.50) SMN1; SMN2NPC1RAB9AMCHR1HRH3
SCHEMBL26764086 0.91 NPC1 (0.50) SMN1; SMN2NPC1RAB9AMCHR1HRH3
SCHEMBL24011213 0.89 MCHR1 (0.57) SMN1; SMN2NPC1RAB9AMCHR1HRH3
SCHEMBL26633890 0.84 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9AMCHR1HRH3
SCHEMBL30306642 0.83 NPC1 (0.51) SMN1; SMN2NPC1RAB9AMCHR1HRH3
SCHEMBL30306654 0.83 CCR3 (0.52) SMN1; SMN2NPC1RAB9AMCHR1HRH3
SCHEMBL26764090 0.83 NPC1 (0.51) SMN1; SMN2NPC1RAB9AMCHR1HRH3
SCHEMBL26764091 0.83 CCR3 (0.52) SMN1; SMN2NPC1RAB9AMCHR1HRH3
SCHEMBL30306649 0.82 MAPT (0.49) SMN1; SMN2NPC1RAB9AMCHR1HRH3
SCHEMBL26764206 0.82 MAPT (0.49) SMN1; SMN2NPC1RAB9AMCHR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115843295-B NAMPT modulators 赛特凯恩蒂克公司 2025-04-15 — — CN disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
CN-115843295-A NAMPT modulators 赛特凯恩蒂克公司 2023-03-24 — — CN disclosed
EP-4146640-A2 NAMPT MODULATORS Cytokinetics, Inc. (US) 2023-03-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT SMN1; SMN2 610/4885NPC1 128/4885RAB9A 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback